Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Jun 8;2(11):1283–1293. doi: 10.1182/bloodadvances.2017015552

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 by The American Society of Hematology

PMC Copyright notice

Figure 6. — mAb-RC3 inhibits human thrombus formation independent of PAR4 variant expression. (A) Representative 3-dimensional reconstructions and (B-E) quantitation of human thrombi formed after 3 minutes of a whole blood thrombosis assay, showing platelets (red, anti-CD9), thrombin (green, thrombin probe), and fibrin (purple, anti-fibrin). (B,C) Pretreatment of blood with mAb-RC3 (RC3, 100 μg/mL) significantly inhibited fibrin formation, but the effect on platelet deposition did not reach significance. (D) This translated to a significant reduction in total thrombus volume. Individual data points are shown. Bars are mean ± standard error of the mean of all N = 18 experiments. *P < .05; not significant (ns) (unpaired Student t test). (E) Pairwise analysis for all individuals, separated by PAR4 genotype, showing a reduction in total thrombus volume in all individuals except the 2 with the lowest baseline response.